Pediatric Cancer – Pipeline Review, H2 2012

Pediatric Cancer – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Pediatric Cancer - Pipeline Review, H2 2012', provides an overview of the Pediatric Cancer therapeutic pipeline. This report provides information on the therapeutic development for Pediatric Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pediatric Cancer. 'Pediatric Cancer - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Pediatric Cancer.
- A review of the Pediatric Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Pediatric Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Pediatric Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Pediatric Cancer pipeline depth and focus of Pediatric Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Pediatric Cancer Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Pediatric Cancer 8
Pediatric Cancer Therapeutics under Development by Companies 10
Pediatric Cancer Therapeutics under Investigation by Universities/Institutes 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Pediatric Cancer Therapeutics – Products under Development by Companies 15
Pediatric Cancer Therapeutics – Products under Investigation by Universities/Institutes 16
Companies Involved in Pediatric Cancer Therapeutics Development 17
Novartis AG 17
Hana Biosciences, Inc. 18
Innogene Kalbiotech Pte Ltd. 19
PharmaMar, S.A. 20
Pediatric Cancer – Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
LBH589 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Marqibo - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Racotumomab - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Vinorelbine + Cyclophosphamide - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Yondelis - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Carboplatin + Etoposide + Autologous bone marrow reinfusion - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
COPP + ABV - Drug Profile 38
Product Description 38
Mechanism of Action 39
R&D Progress 40
Therapeutic Autologous Dendritic Cells + Indinavir Sulfate + Stem Cell Transplantation - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 42
SCH 717454 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
MLN8237 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
SVV-001 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Vorinostat + Etoposide - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Itraconazole - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Pediatric Cancer Therapeutics – Drug Profile Updates 48
Pediatric Cancer Therapeutics – Discontinued Products 53
Pediatric Cancer Therapeutics - Dormant Products 54
Pediatric Cancer – Product Development Milestones 55
Featured News & Press Releases 55
Jul 11, 2012: Scientists Develop New Strategy To Overcome Drug-Resistant Childhood Cancer 55
Feb 24, 2010: Enzon Opens Pediatric Study Of PEG-SN38 56
Jun 01, 2009: Cytokinetics Announces Non-Clinical Data Relating To GSK-923295 Presented At The 2009 Annual Meeting Of The American Society Of Clinical Oncology 56
Oct 23, 2008: Neotropix Announces Presentation Of Preclinical Results Of NTX-010 57
Jun 19, 2007: OSI Pharmaceuticals Begins Clinical Development Program of OSI-906 in Patients with Advanced Solid Tumors 57
Nov 02, 2006: Ziopharm Announces Preclinical Data Of ZIO-201 In Pediatric Cancers 58
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 60
Disclaimer 60

List of Tables
Number of Products Under Development for Pediatric Cancer, H2 2012 8
Products under Development for Pediatric Cancer – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
Novartis AG, H2 2012 17
Hana Biosciences, Inc., H2 2012 18
Innogene Kalbiotech Pte Ltd., H2 2012 19
PharmaMar, S.A., H2 2012 20
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 26
Pediatric Cancer Therapeutics – Drug Profile Updates 48
Pediatric Cancer Therapeutics – Discontinued Products 53
Pediatric Cancer Therapeutics – Dormant Products 54

List of Figures
Number of Products under Development for Pediatric Cancer, H2 2012 8
Products under Development for Pediatric Cancer – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Pre-Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Route of Administration, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Molecule Type, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 26